BHRF1 antisense oligonucleotide inhibits anti-apoptosis of nasopharyngeal carcinoma cells.
Epstein-Barr virus gene BHRF1 has homology with proto-oncogene bcl-2, which can protect cells from apoptosis, thus, it may play important roles in oncogenesis and affect treatment of EBV-related cancers. We used BHRF1 antisense oligonucleotide to block its expression in nasopharyngeal carcinoma cell line, CNE2. The results showed that after blocking by BHRF1 antisense oligonucleotide, CNE2 cells had higher S-phase cell percentage, more susceptibility to radiation with weaker ability of proliferation, colony forming efficiency and tumor development in nude mice after radiation. Our results suggest that BHRF1 antisense oligonucleotide could inhibit BHRF1 anti-apoptotic ability, and may contribute to the treatment of EBV-related cancers.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Affiliations: Microbiology and Tumorbiology Center, Karolinska Institute, Stockholm S-17177, Sweden.
Publication date: December 1, 1999
More about this publication?
- The International Journal of Molecular Medicine is a monthly, peer-reviewed journal devoted to the publication of high quality studies related to the molecular mechanisms of human disease. The journal welcomes research on all aspects of molecular and clinical research, ranging from biochemistry to immunology, pathology, genetics, human genomics, microbiology, molecular pathogenesis, molecular cardiology, molecular surgery and molecular psychology.
The International Journal of Molecular Medicine aims to provide an insight for researchers within the community in regard to developing molecular tools and identifying molecular targets for the diagnosis and treatment of a diverse number of human diseases.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites